| |
September 14, 2023 | 1:00 PM ET Over 50% of life sciences companies are doing patient finding. Are you? Register now to learn about patient finding best practices, use cases and common pitfalls. AIML is here. Be ready with Trinity Life Sciences. .png)
|
|
Today’s Big NewsAug 25, 2023 |
| By James Waldron RayzeBio has already persuaded investors to hand over more than $400 million to pursue its targeted radiation approach to treating cancer. Now, with its lead product in phase 3 trials, the biotech is eyeing up an IPO to push its plans forward. |
|
|
|
| Philadelphia, PA |  |
|
|
By Nick Paul Taylor Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will follow patients for around six years. |
By Helen Floersh With the help of advanced algorithms and DNA sequencing techniques, scientists have decoded the Y chromosome in full for the first time. |
By Max Bayer Leaps by Bayer's Juergen Eckhardt adds innovation role at Bayer. Exelixis has named Amy Peterson as its new chief medical officer, replacing Vicki Goodman. Mirati CFO follows CEO out of the exits. |
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now. 
|
|
By Angus Liu Moderna is considering pairing an mRNA cancer vaccine candidate with a CAR-T therapy from China's CARsgen. GSK's Shingrix showed 100% efficacy in a Chinese post-marketing trial. Glenmark and Teva have reached a settlement with U.S. prosecutors over price-fixing charges. |
By Fraiser Kansteiner In a phase 3 study, semaglutide at the 2.4 mg dose bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction. The drug also led to greater improvements in exercise function and more weight loss versus a dummy drug, according to study results published in The New England Journal of Medicine Friday. |
By Paige Minemyer Cigna is eliminating prior authorization requirements from 600 diagnostic codes in a bid to streamline the experience for both members and providers. |
By Zoey Becker Exelixis' drug proved its worth in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors, so much so that an independent board unanimously recommended an early stop. |
By Angus Liu Add another failed trial to the list of setbacks for Merck and Eisai’s combination of Keytruda and Lenvima. The companies have decided to shut down a phase 3 study testing the PD-1/TKI combo in first-line head and neck cancer. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
October 16-17 | Boston, MA Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book you seat today and save $200! |
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
